SCHEMBL21597670

SCHEMBL21597670

CCOC(=O)C1CCCc2c1sc(NC(=O)C1CC1)c2C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
ALDH1A1 P00352 7/20 0.47
HPGD P15428 2/20 0.47
MAPK1 P28482 1/20 0.47
KDM4E B2RXH2 4/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 2/20 0.44
GAA P10253 2/20 0.44
HIF1A Q16665 1/20 0.44
TSHR P16473 1/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 1/20 0.43
FLT3 P36888 1/20 0.42
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
CNR2 P34972 2/20 0.40
CNR1 P21554 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21597739 0.87 MAPT (0.47) MAPTALDH1A1HPGDMAPK1KDM4E
SCHEMBL21597774 0.86 CNR2 (0.45) MAPTALDH1A1HPGDMAPK1KDM4E
SCHEMBL21603874 0.79 KDM4E (0.50) MAPTALDH1A1HPGDMAPK1KDM4E
SCHEMBL21603868 0.78 MAPT (0.58) MAPTALDH1A1HPGDMAPK1KDM4E
SCHEMBL21597242 0.78 ALDH1A1 (0.68) MAPTALDH1A1HPGDMAPK1KDM4E
SCHEMBL21597418 0.77 MAPT (0.49) MAPTALDH1A1HPGDMAPK1KDM4E
Water SCHEMBL21597714 0.76 KDM4E (0.47) MAPTALDH1A1KDM4EHSD17B10GAA
SCHEMBL21597744 0.74 MAPT (0.53) MAPTALDH1A1HPGDMAPK1KDM4E
SCHEMBL21603937 0.74 CNR2 (0.49) MAPTALDH1A1HPGDMAPK1KDM4E
SCHEMBL21597513 0.73 TP53 (0.53) MAPTALDH1A1HPGDMAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MAPT 2356/4885ALDH1A1 233/4885HPGD 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.